Pregled bibliografske jedinice broj: 1175854
Modifying the effects of cytoreductive drugs on kidney function in myeloproliferative neoplasms
Modifying the effects of cytoreductive drugs on kidney function in myeloproliferative neoplasms // Pharmacology, 106 (2021), 7-8; 451-452 doi:10.1159/000516894 (međunarodna recenzija, komentar, stručni)
CROSBI ID: 1175854 Za ispravke kontaktirajte CROSBI podršku putem web obrasca
Naslov
Modifying the effects of cytoreductive drugs on
kidney function in myeloproliferative neoplasms
Autori
Krečak, Ivan ; Lucijanić, Marko
Izvornik
Pharmacology (0031-7012) 106
(2021), 7-8;
451-452
Vrsta, podvrsta i kategorija rada
Radovi u časopisima, komentar, stručni
Ključne riječi
cytoreductive drugs ; kidney function ; myeloproliferative neoplasms
Sažetak
This Letter is a comment on the retrospective study of Kwiatkowski et al, which has demonstrated that the use of anagrelide in patients with essential thrombocythemia (ET) may be associated with worsening of kidney function. In this Letter, we emphasize the clinical importance of chronic kidney disease in patients with myeloproliferative neoplasms and discuss the reasons which could have lead to an increased risk of kidney dysfunction in ET patients treated with anagrelide. Finally, we suggest the authors of the original study to perform additional analyses on their dataset.
Izvorni jezik
Engleski
Znanstvena područja
Kliničke medicinske znanosti
POVEZANOST RADA
Ustanove:
Medicinski fakultet, Zagreb,
Opća bolnica Šibenik,
Klinička bolnica "Dubrava"
Citiraj ovu publikaciju:
Časopis indeksira:
- Current Contents Connect (CCC)
- Web of Science Core Collection (WoSCC)
- Science Citation Index Expanded (SCI-EXP)
- SCI-EXP, SSCI i/ili A&HCI
- Scopus
- MEDLINE
